Chicago: Brain-Penetrant Microtubule Stabilizer in Tauopathy Mice
Another preclinical study presented at the ICAD capitalized on tau’s microtubule-binding property...
6397 RESULTS
Sort By:
Another preclinical study presented at the ICAD capitalized on tau’s microtubule-binding property...
The International Conference on Alzheimer’s Disease featured some noteworthy preclinical and basic science tau developments...
Comparing neuropsychological test results against age-adjusted norms is one way of determining whether an individual might be facing impending dementia...
Chicago: Studies Probe Diminishing Placebo Decline, Part 1 Chicago: Studies Probe Diminishing Placebo Decline, Part 2 Chicago: ICAD Offered Mix Bag of Setbacks and Hopeful News Chicago: Trial Design Bedevils Search for New AD Drugs, Part 1 Chicago: The Ph
At the International Conference for Alzheimer’s Disease, investigators reported results on a range of different clinical trials...
One way to get the lowdown on someone is to check out the person’s closest friends and colleagues...
In mammals, molecular chaperones may help stave off neurodegenerative disease by steering proteins away from abnormal, toxic conformations...
The accumulation of phagocytic microglia in the brain could be good or bad for AD patients...
It’s instructive to learn how pharmaceutical companies are navigating the transition for new experimental AD drugs from Phase 2 to 3...
A paper suggests that a non-invasive imaging procedure detects buildup of amyloid-β...
The story of how Elan/Wyeth’s antibody therapy fared at the ICAD is one of the stranger tales in AD drug development...
An oral antihistamine has emerged in the race to become the first AD drug with stronger, more lasting benefit than any of the drugs currently available...
Of all clinical trials reported at the ICAD, one targeting the protein tau was the <em>therapy du jour</em>...
Companies have dealt with the uncertainty created by the Phase 2 problem in clinical trial design in several ways...
On the last day of ICAD, recent disappointing AD trial results were put into a broader perspective...
No filters selected